NexGel, Inc. filed a Form 8-K on November 18, 2026, disclosing the election of Aviv Argaman as an independent director effective November 12, 2026, and the establishment of a special committee to evaluate a proposed business combination with Fountainhead LifeSciences and its affiliates.

Key Highlights

  • New director elected: Aviv Argaman, age 36 and founder of Asymmetry Point Capital LLC, was elected to the NexGel board on November 12, 2026, determined by the board to be independent under Nasdaq Listing Rules.
  • Special committee formed: On November 18, 2026, the board established a special committee consisting of Steve Ciardiello (Chair), Jerome Zeldis, and Aviv Argaman to evaluate and negotiate the proposed Merger.
  • Argaman's indirect financial interest: Through Asymmetry Point, Mr. Argaman holds $2.0 million aggregate principal amount of convertible promissory notes issued in 2026, bearing 10% interest.
  • Conversion terms: Asymmetry Point irrevocably elected to convert its notes into 363,636 shares of common stock at $5.50 per share, plus approximately 5,868 shares for accrued interest through September 30, 2026, contingent on Merger completion.
  • Existing warrant modification: The exercise price of Asymmetry Point's Existing Note Warrants was reduced to $13.00 per share from $16.00 per share, with the warrants subject to surrender at the Conversion Closing.
  • Reverse stock split note: Share and per-share amounts in the filing give effect to a 1-for-20 reverse stock split effective October 12, 2026.

NexGel Discloses Argaman Appointment and Special Committee Details

According to the filing, NexGel, Inc. (NASDAQ:NXGL) elected Aviv Argaman as a director on November 12, 2026, effective immediately, to serve until the company's next annual meeting of stockholders. The board determined Mr. Argaman is an independent director under the Nasdaq Listing Rules. The filing states there is no arrangement or understanding between Mr. Argaman and any other person under which he was selected, and no family relationships exist between Mr. Argaman and any director or executive officer of the company.

The filing describes Mr. Argaman as a full-time professional investor since 2021. Since 2024, he has served as founder and manager of Asymmetry Point Capital LLC, which acts as general partner and investment manager of Asymmetry Point LP and its feeder fund, Asymmetry Point CF I. From 2022 to 2024, he founded and managed Asymmetry Point Capital Ltd., an Israeli investment firm. Prior to 2021, he worked in engineering and management consulting, and holds a double B.Sc. in Electrical Engineering and Physics from the Technion, Israel Institute of Technology.

The filing discloses that Asymmetry Point purchased $2.0 million aggregate principal amount of the company's convertible promissory notes in private placements on April 17, 2026 and July 2, 2026, on the same terms as other investors. The filing also notes that Asymmetry Point did not participate in the New Capital Financing. Regarding the special committee, the filing states that each member other than Mr. Zeldis holds notes that would automatically convert into common stock if the Merger is completed. Mr. Argaman's standard non-employee director compensation has not yet been determined, according to the filing. The company disclosed that it has not entered into a definitive agreement for the Merger.

What Was Disclosed

NexGel filed an 8-K disclosing the November 12, 2026 election of Aviv Argaman as an independent director and the November 18, 2026 formation of a special committee to evaluate a proposed merger, along with Argaman's indirect financial interests in the company through Asymmetry Point.